Overproduction of active efflux pump and variations of OprD dominate in imipenem-resistant Pseudomonas aeruginosa isolated from patients with bloodstream infections in Taiwan

BMC Microbiology

Volumn 16, Issue 1, 2016, Pages

  Kao, Cheng Yen ^a   Chen, Shu Sheng ^a   Hung, Kuei Hsiang ^a   Wu, Hsiu Mei ^a   Hsueh, Po Ren ^b   Yan, Jing Jou ^c   Wu, Jiunn Jong ^a,d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Efflux pump; Imipenem; OprD; Pseudomonas aeruginosa; lactamase

Indexed keywords

AMIKACIN; AZTREONAM; BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; CLOXACILLIN; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; ANTIINFECTIVE AGENT; OPRD PROTEIN, PSEUDOMONAS AERUGINOSA; PORIN; STOP CODON;

AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; CONTROLLED STUDY; DISEASE SURVEILLANCE; ENZYME ANALYSIS; ENZYME SYNTHESIS; GENETIC VARIATION; HUMAN; MICROBIAL DIVERSITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPRD GENE; POINT MUTATION; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS; STOP CODON; BACTEREMIA; BIOSYNTHESIS; DRUG EFFECTS; GENETICS; INDEL MUTATION; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PSEUDOMONAS INFECTION; TAIWAN;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; CODON, TERMINATOR; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; IMIPENEM; INDEL MUTATION; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; PORINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TAIWAN;

EID: 84978218391     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/s12866-016-0719-2     Document Type: Article

References (38)

1. Gaspar MC, Couet W, Olivier JC, Pais AA, Sousa JJ. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur J Clin Microbiol Infect Dis. 2013;32:1231-52.
2. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22:582-610.
3. Strateva T, Yordanov D. Pseudomonas aeruginosa-a phenomenon of bacterial resistance. J Med Microbiol. 2009;58:1133-48.
4. Masterton RG. The new treatment paradigm and the role of carbapenems. Int J Antimicrob Agents. 2009;33:105-10.
5. Gutierrez O, Juan C, Cercenado E, Navarro F, Bouza E, Coll P, et al. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother. 2007;51:4329-35.
6. Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:4783-8.
7. Riera E, Cabot G, Mulet X, Garcia-Castillo M, del Campo R, Juan C, et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother. 2011;66:2022-7.
8. Andrasevic AT, Dowzicky MJ. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004-2009). Int J Antimicrob Agents. 2012;39:115-23.
9. Hawser S, Hoban D, Bouchillon S, Badal R, Carmeli Y, Hawkey P. Antimicrobial susceptibility of intra-abdominal gram-negative bacilli from Europe: SMART Europe 2008. Eur J Clin Microbiol Infect Dis. 2011;30:173-9.
10. Lin KY, Lauderdale TL, Wang JT, Chang SC. Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: Prevalence, risk factors, and impact on outcome of infections. J Microbiol Immunol Infect. 2014. doi: 10.1016/j.jmii.2014.01.005.
11. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf.
12. VIM endemicity. J Antimicrob Chemother. 2005;56:761-4.
13. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2006;50:1633-41.
14. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211-33.
15. Barnaud G, Benzerara Y, Gravisse J, Raskine L, Sanson-Le Pors MJ, Labia R, et al. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob Agents Chemother. 2004;48:1040-2.
16. Rodriguez-Martinez JM, Poirel L, Nordmann P. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009;53:1766-71.
17. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA; 2009.
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, twenty-third informational supplement, M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA; 2013.
19. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.
20. Chu G, Vollrath D, Davis RW. Separation of large DNA molecules by contour-clamped homogeneous electric fields. Science. 1986;234:1582-5.
21. Yan JJ, Hsueh PR, Ko WC, Luh KT, Tsai SH, Wu HM, Wu JJ. Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother. 2001;45:2224-8.
22. Gales AC, Menezes LC, Silbert S, Sader HS. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. J Antimicrob Chemother. 2003;52:699-702.
23. Smith Moland E, Hanson ND, Herrera VL, Black JA, Lockhart TJ, Hossain A, et al. Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother. 2003;51:711-4.
24. GIM-1, encoding a new subclass of metallo-beta-lactamase. Antimicrob Agents Chemother. 2004;48:4654-61.
25. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48:15-22.
26. Lee K, Yum JH, Yong D, Lee HM, Kim HD, Docquier JD, et al. Novel acquired metallo-beta-lactamase gene, bla(SIM-1), in a class 1 integron from Acinetobacter baumannii clinical isolates from Korea. Antimicrob Agents Chemother. 2005;49:4485-91.
27. Poirel L, Brinas L, Fortineau N, Nordmann P. Integron-encoded GES-type extended-spectrum beta-lactamase with increased activity toward aztreonam in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:3593-7.
28. Yan JJ, Hsueh PR, Lu JJ, Chang FY, Ko WC, Wu JJ. Characterization of acquired beta-lactamases and their genetic support in multidrug-resistant Pseudomonas aeruginosa isolates in Taiwan: the prevalence of unusual integrons. J Antimicrob Chemother. 2006;58:530-6.
29. Mirsalehian A, Feizabadi M, Nakhjavani FA, Jabalameli F, Goli H, Kalantari N. Detection of VEB-1, OXA-10 and PER-1 genotypes in extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa strains isolated from burn patients. Burns. 2010;36:70-4.
30. Yang FC, Yan JJ, Hung KH, Wu JJ. Characterization of ertapenem-resistant Enterobacter cloacae in a Taiwanese university hospital. J Clin Microbiol. 2012;50:223-6.
31. Pages JM, Masi M, Barbe J. Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med. 2005;11:382-9.
32. Davies TA, Marie Queenan A, Morrow BJ, Shang W, Amsler K, He W, et al. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09. J Antimicrob Chemother. 2012;66:2298-307.
33. Kao CY, Sheu BS, Wu JJ. CsrA regulates Helicobacter pylori J99 motility and adhesion by controlling flagella formation. Helicobacter. 2014;19:443-54.
34. Savli H, Karadenizli A, Kolayli F, Gundes S, Ozbek U, Vahaboglu H. Expression stability of six housekeeping genes: A proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR. J Med Microbiol. 2003;52:403-8.
35. Siguier P, Perochon J, Lestrade L, Mahillon J, Chandler M. ISfinder: the reference centre for bacterial insertion sequences. Nucleic Acids Res. 2006;34(Database issue):D32-6.
36. van Mansfeld R, Jongerden I, Bootsma M, Buiting A, Bonten M, Willems R. The population genetics of Pseudomonas aeruginosa isolates from different patient populations exhibits high-level host specificity. PLoS One. 2010;5:e13482.
37. Hancock RE, Brinkman FS. Function of pseudomonas porins in uptake and efflux. Annu Rev Microbiol. 2002;56:17-38.
38. Epp SF, Kohler T, Plesiat P, Michea-Hamzehpour M, Frey J, Pechere JC. C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem. Antimicrob Agents Chemother. 2001;45:1780-7.